VAERS reports by lot

GSK DTaP/Tdap lot TX77L: VAERS reports

24 VAERS reports list lot TX77L as a GSK DTaP/Tdap vaccine, received between 2023-12-19 and 2024-10-09. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
24
Reports
0%
Marked serious
0
With a death outcome
9
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
Injection-site / Local reaction2362%
Dermatological (non-injection-site)411%
Allergic / Anaphylactic38%
General / Systemic (non-local)38%
Neurological13%
Cardiac / Cardiovascular13%
Respiratory13%
Psychiatric / Neuropsychiatric13%

Where reports came from

U.S. state of the reporter, where given (top 12).

Texas5
California3
Florida2
North Carolina2
Maryland2
Indiana2
Arizona1
Virginia1
Illinois1
Massachusetts1
West Virginia1
New York1

Reports by month received

2023-121
2024-026
2024-033
2024-046
2024-052
2024-063
2024-071
2024-091
2024-101

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.